ArticleRenal failure2025
The predictive value of tacrolimus intrapatient variability and time in therapeutic range for renal transplant outcomes.
Article in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Differences in Early Tacrolimus Exposure in Kidney Transplant Recipients With and Without CYP3A5 Genotype-Guided Tacrolimus Dosing.Clinical and translational science · 2026Article
- Comparing Whole-Blood and Plasma Tacrolimus Intra-Patient Variability for Predicting Allograft Rejection in Kidney Transplantation.Clinical and translational science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTacrolimus is key in renal transplantation. This study evaluated optimal intrapatient variability (IPV) and time in therapeutic range (TTR) thresholds and association with renal outcomes.
methodsThis single-center study (1999-2018) had a mean follow-up of 3 years. All patients received tacrolimus-based immunosuppression, and excluded those switching from cyclosporin. Receiver operating characteristic curves evaluated IPV and TTR cutoff values for biopsy-proved acute rejection (BPAR). Cox regression,
resultsThe cohort included 463 patients (mean age 47.3 years; 44.1% female). Most received cadaveric grafts (66.4%) and ABO-compatible transplants (97.4%). Preexisting diabetes and hypertension were present in 14.7% and 63.7%, respectively. Mean tacrolimus trough level was 7.28 ± 1.92 ng/mL. Patients with IPV ≥25.6% had increased doubling of serum creatinine (DSCr) at 6-12 months (
conclusionIPV and TTR are valuable for predicting renal transplant outcomes, with IPV demonstrating stronger predictive ability. Minimizing IPV through frequent monitoring and adherence support could enhance graft survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.